These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35933070)

  • 21. Locomotion of T cells from patients with cutaneous T-cell lymphoma (Sézary syndrome and mycosis fungoides).
    Gupta S; Safai B; Edelson R; Parrott D; Good R
    Cell Immunol; 1980 Mar; 50(1):195-201. PubMed ID: 6967357
    [No Abstract]   [Full Text] [Related]  

  • 22. Single-Cell RNA Sequencing Unveils the Clonal and Transcriptional Landscape of Cutaneous T-Cell Lymphomas.
    Gaydosik AM; Stonesifer CJ; Khaleel AE; Geskin LJ; Fuschiotti P
    Clin Cancer Res; 2022 Jun; 28(12):2610-2622. PubMed ID: 35421230
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Leu-8/CD7 antigen expression by CD3+ T cells: comparative analysis of skin and blood in mycosis fungoides/Sézary syndrome relative to normal blood values.
    Wood GS; Hong SR; Sasaki DT; Abel EA; Hoppe RT; Warnke RA; Morhenn VB
    J Am Acad Dermatol; 1990 Apr; 22(4):602-7. PubMed ID: 1690762
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Survival and Prognostic Factors in Patients with Aggressive Cutaneous T-cell Lymphomas.
    Franceschi J; Ehret M; Visseaux L; Durlach A; Barbe C; Durot É; Grange F
    Acta Derm Venereol; 2022 Mar; 102():adv00676. PubMed ID: 35083494
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lymph node involvement by mycosis fungoides and Sézary syndrome mimicking angioimmunoblastic T-cell lymphoma.
    LeBlanc RE; Lefterova MI; Suarez CJ; Tavallaee M; Kim YH; Schrijver I; Kim J; Gratzinger D
    Hum Pathol; 2015 Sep; 46(9):1382-9. PubMed ID: 26193796
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Absence of T(H)2 cytokine messenger RNA expression in CD30-negative primary cutaneous large T-cell lymphomas.
    Vermeer MH; Tensen CP; van der Stoop PM; van Oostveen HW; Lund M; Scheper RJ; Willemze R
    Arch Dermatol; 2001 Jul; 137(7):901-5. PubMed ID: 11453809
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mycosis fungoides and Sézary syndrome following dupilumab treatment: experience of two Italian tertiary care centres.
    Buffon S; Alberti Violetti S; Avallone G; Venegoni L; Marzano AV; Mastorino L; Fava P; Ribero S; Quaglino P; Ortoncelli M; Ferrucci SM
    Clin Exp Dermatol; 2023 Nov; 48(12):1376-1378. PubMed ID: 37596961
    [No Abstract]   [Full Text] [Related]  

  • 28. Clinical and Histological Characteristics of Mycosis Fungoides and Sézary Syndrome: A Retrospective, Single-centre Study of 43 Patients from Eastern Denmark.
    Nielsen PR; Eriksen JO; Wehkamp U; Lindahl LM; Gniadecki R; Fogh H; Fabricius S; Bzorek M; Ødum N; Gjerdrum LM
    Acta Derm Venereol; 2019 Dec; 99(13):1231-1236. PubMed ID: 31620804
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comment on B ratings for erythrodermic cutaneous T-cell lymphoma.
    Vonderheid E
    Eur J Cancer; 2018 Sep; 101():281-283. PubMed ID: 30017384
    [No Abstract]   [Full Text] [Related]  

  • 30. Mycosis fungoides and Sézary syndrome: Australian clinical practice statement.
    Bhabha FK; McCormack C; Wells J; Campbell BA; Newland K; Lade S; Buelens O; Joske D; Shortt J; Mapp S; Radeski D; Hertzberg M; Khot A; Van Der Weyden C; Khoo C; Hawkes E; Prince HM
    Australas J Dermatol; 2021 Feb; 62(1):e8-e18. PubMed ID: 33368169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Primary cutaneous T-cell lymphomas other than mycosis fungoides and Sézary syndrome. Part I: Clinical and histologic features and diagnosis.
    Stoll JR; Willner J; Oh Y; Pulitzer M; Moskowitz A; Horwitz S; Myskowski P; Noor SJ
    J Am Acad Dermatol; 2021 Nov; 85(5):1073-1090. PubMed ID: 33940098
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study.
    Querfeld C; Thompson JA; Taylor MH; DeSimone JA; Zain JM; Shustov AR; Johns C; McCann S; Lin GHY; Petrova PS; Uger RA; Molloy N; Shou Y; Akilov OE
    Lancet Haematol; 2021 Nov; 8(11):e808-e817. PubMed ID: 34627593
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interleukin 4 and interferon-gamma expression of the dermal infiltrate in patients with erythroderma and mycosis fungoides. An immuno-histochemical study.
    Sigurdsson V; Toonstra J; Bihari IC; Bruijnzeel-Koomen CA; van Vloten WA; Thepen T
    J Cutan Pathol; 2000 Oct; 27(9):429-35. PubMed ID: 11028812
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Benefit/risk Ratio of Low-dose Methotrexate in Cutaneous Lesions of Mycosis Fungoides and Sézary Syndrome.
    Alenezi F; Girard C; Bessis D; Guillot B; Du-Thanh A; Dereure O
    Acta Derm Venereol; 2021 Feb; 101(2):adv00384. PubMed ID: 33313939
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CCR4 is expressed on infiltrating cells in lesional skin of early mycosis fungoides and atopic dermatitis.
    Sugaya M; Morimura S; Suga H; Kawaguchi M; Miyagaki T; Ohmatsu H; Fujita H; Sato S
    J Dermatol; 2015 Jun; 42(6):613-5. PubMed ID: 25809616
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC).
    Olsen E; Vonderheid E; Pimpinelli N; Willemze R; Kim Y; Knobler R; Zackheim H; Duvic M; Estrach T; Lamberg S; Wood G; Dummer R; Ranki A; Burg G; Heald P; Pittelkow M; Bernengo MG; Sterry W; Laroche L; Trautinger F; Whittaker S;
    Blood; 2007 Sep; 110(6):1713-22. PubMed ID: 17540844
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytologic evaluation of lymphadenopathy associated with mycosis fungoides and Sezary syndrome: role of immunophenotypic and molecular ancillary studies.
    Pai RK; Mullins FM; Kim YH; Kong CS
    Cancer; 2008 Oct; 114(5):323-32. PubMed ID: 18798522
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New aspects of the clinicopathological features and treatment of mycosis fungoides and Sézary syndrome.
    Furue M; Kadono T
    J Dermatol; 2015 Oct; 42(10):941-4. PubMed ID: 26432429
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Flow cytometric detection of peripheral blood involvement by mycosis fungoides and Sézary syndrome using T-cell receptor Vbeta chain antibodies and its application in blood staging.
    Feng B; Jorgensen JL; Jones D; Chen SS; Hu Y; Medeiros LJ; Wang SA
    Mod Pathol; 2010 Feb; 23(2):284-95. PubMed ID: 19935642
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bilateral breast involvement in Sézary syndrome.
    Balci P; Undar B; Yilmaz E; Seçil M; Ozsan H; Canda T
    Eur Radiol; 2001; 11(12):2468-71. PubMed ID: 11734942
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.